Efficacy of Oncolytic Herpes Simplex Virus T-VEC Combined with BET Inhibitors as an Innovative Therapy Approach for NUT Carcinoma

Efficacy of Oncolytic Herpes Simplex Virus T-VEC Combined with BET Inhibitors as an Innovative Therapy Approach for NUT Carcinoma

NUT carcinoma (NC) is an extremely aggressive tumor and current treatment regimens offer patients a median survival of six months only. This article reports on the first in vitro studies using immunovirotherapy as a promising therapy option for NC and its feasible combination with BET inhibitors (iB...

Full description

Bibliographic Details
Main Authors: Paul V. Ohnesorge, Susanne Berchtold, Julia Beil, Simone A. Haas, Irina Smirnow, Andrea Schenk, Christopher A. French, Nhi M. Luong, Yeying Huang, Birgit Fehrenbacher, Martin Schaller, Ulrich M. Lauer
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Series:Cancers
Subjects:
virotherapy
talimogene laherparepvec
T-VEC
NUT carcinoma
BET inhibitors
combination therapy
Online Access:https://www.mdpi.com/2072-6694/14/11/2761

Internet

https://www.mdpi.com/2072-6694/14/11/2761

Similar Items